Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tenax Therapeutics (TENX) Liabilities and Shareholders Equity (2016 - 2017)

Historic Liabilities and Shareholders Equity for Tenax Therapeutics (TENX) over the last 6 years, with Q3 2017 value amounting to $11.0 million.

  • Tenax Therapeutics' Liabilities and Shareholders Equity fell 8157.34% to $11.0 million in Q3 2017 from the same period last year, while for Dec 2017 it was $43.6 million, marking a year-over-year decrease of 7037.32%. This contributed to the annual value of $23.3 million for FY2016, which is N/A changed from last year.
  • As of Q3 2017, Tenax Therapeutics' Liabilities and Shareholders Equity stood at $11.0 million, which was down 8157.34% from $13.4 million recorded in Q2 2017.
  • In the past 5 years, Tenax Therapeutics' Liabilities and Shareholders Equity ranged from a high of $73.0 million in Q4 2015 and a low of $3.0 million during Q1 2013
  • Over the past 4 years, Tenax Therapeutics' median Liabilities and Shareholders Equity value was $19.2 million (recorded in 2017), while the average stood at $30.0 million.
  • Per our database at Business Quant, Tenax Therapeutics' Liabilities and Shareholders Equity tumbled by 2320.87% in 2013 and then plummeted by 8157.34% in 2017.
  • Tenax Therapeutics' Liabilities and Shareholders Equity (Quarter) stood at $3.2 million in 2013, then soared by 2194.73% to $73.0 million in 2015, then tumbled by 68.02% to $23.3 million in 2016, then tumbled by 52.86% to $11.0 million in 2017.
  • Its last three reported values are $11.0 million in Q3 2017, $13.4 million for Q2 2017, and $19.2 million during Q1 2017.